A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
37actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-06 | actual | When the study began enrolling |
| Primary completion | 2025-05-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-27 | actual | The whole study's end, after follow-up |
| First posted | 2025-02-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers Sickle Cell Disease, Thalassemia
Interventions
- Drug: Etavopivat
- Drug: Digoxin
- Drug: Pitavastatin
- Drug: Metformin
- Drug: Midazolam
- Drug: Rosuvastatin
Primary outcomes
what the primary-completion date above is the date OFCmax, digoxin, SD: Maximum observed digoxin plasma concentration with and without etavopivat at steady state
measured Day 1 and day 3 after digoxin administration
AUC0-inf, digoxin, SD: Area under the digoxin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady state
measured Day 1 and day 3 after digoxin administration
Cmax, rosuvastatin, SD: Maximum observed rosuvastatin plasma concentration with and without etavopivat at steady state
measured Day 1 after rosuvastatin administration
AUC0-inf, rosuvastatin, SD: Area under the rosuvastatin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady state
measured Day 1 after rosuvastatin administration
Cmax, midazolam, SD: Maximum observed midazolam plasma concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state
measured Day 1 after midazolam administration
AUC0-inf, midazolam, SD: Area under the midazolam plasma concentration-time curve from 0 hours and extrapolated to infinity without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state
measured Day 1 after midazolam administration
Cmax, pitavastatin, SD: Maximum observed pitavastatin plasma concentration with and without etavopivat at steady state
measured Day 1 and day 3 after pitavastatin administration
AUC0-inf, pitavastatin, SD: Area under the pitavastatin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady state
measured Day 1 and day 3 after pitavastatin administration
Cmax, metformin, SD: Maximum observed metformin plasma concentration with and without etavopivat at steady state
measured Day 1 and day 3 after metformin administration
AUC0-inf, metformin, SD: Area under the metformin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady state
measured Day 1 and day 3 after metformin administration
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed